About: http://data.cimple.eu/news-article/b43515b91f911cfd60e3732f5978f4b36c87c950f600fffecd346dc2

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/b43515b91f911cfd60e3732f5978f4b36c87c950f600fffecd346dc2 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	US pharmaceutical giant Johnson and Johnson announced Monday an immediate cut in the price of its tuberculosis treatment course -- a move NGOs have long been calling for. Bedaquiline, sold under the brand name Sirturo, was approved for medicinal use in the United States in 2012, becoming the first new tuberculosis drug in 40 years to be given the green light. Johnson and Johnson said it would make its bedaquiline tablets available to the Stop TB Partnership in around 135 low- and middle-income countries at $340 instead of $400 for a six-month treatment course. The initiative aims to reach at least 125,000 patients this year and could save national TB programmes up to $16 million, the UN-hosted partnership said in a statement. The medical charity Doctors Without Borders (MSF) welcomed the news but said the price should come down further, and be extended to more countries. "While we anxiously wait for more affordable generic versions of bedaquiline to become available... today's price reduction is a helpful step," said Lara Dovifat, campaigns and advocacy advisor at MSF's Access Campaign. A bacterial, airborne respiratory disease, TB remains the planet's deadliest infectious killer, according to the World Health Organization. The WHO said 10 million people fell ill with TB in 2018, and 1.5 million died. Incidence and deaths have been declining steadily over the last several years, said the Stop TB Partnership. However, in 2018 there were nearly 500,000 new cases of drug-resistent tuberculosis (DR-TB). "This new agreement is a welcome development and one that will help us move closer to the United Nations High-Level meeting target of treating 1.5 million people with DR-TB by 2022," said Lucica Ditiu, the Stop TB Partnership's executive director. "Even though these days we fight against the new COVID-19 pandemic, we cannot let this new virus stop our progress against TB." rjm/pvh
schema:headline	Johnson and Johnson cuts price of anti-TB tablets
schema:mentions	Médecins Sans Frontières Master of Finance House of Lara Respiratory disease The Who Pharmaceutical industry Tuberculosis Ebola virus disease Planet World Health Organization United Nations Pandemic United States Severe acute respiratory syndrome coronavirus 2 Airborne disease Bedaquiline Stop TB Partnership Tuberculosis management Move Closer PVH (company)
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-07-06 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	71 (xsd:integer)

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software